Comparison tool

Pentadecapeptide vs BPC-157 side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

PentadecapeptideBPC-157

Share this peptide comparison

Property	Pentadecapeptide	BPC-157
Category	Healing	Healing
Also known as	BPC-157 Full Sequence, Stable Gastric Pentadecapeptide	Body Protection Compound-157, Pentadecapeptide BPC 157
FDA approved	No	No
Clinical status	Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Phase 2 recruiting (NCT07437547); investigational. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Tissue healing, gut health, injury recovery	Injury recovery, gut healing, joint and tendon repair
How it works	Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.	The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.
Typical dosing	Limited community data available · See research protocols	250-500 mcg twice daily · 1-2x daily
Research dosing	250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection	250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic
Typical duration	4-12 weeks typical	4-12 weeks in most research protocols
Administration	Subcutaneous injection	Subcutaneous injection near injury site, or systemic
Timing	Morning and evening; sometimes aligned with injury-related activity timing With or without food	Morning and evening (or near injury site timing) With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.) Nausea (Reported side effect in the source.) Dizziness (Reported side effect in the source.) +1 more Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)	Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.) Nausea (Listed by the source without frequency or causality information.) Dizziness (Listed by the source without frequency or causality information.) +6 more Injection site reactions (Listed by the source without frequency or causality information.) Fatigue (Listed by the source without frequency or causality information.) Headache (Listed by the source without frequency or causality information.) May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.) Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.) Limited long-term human safety data (The source itself notes limited long-term human safety information.)
Research summary	The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.	According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.
References	Source Source +3 more Source Source Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Pentadecapeptide

BPC-157

Category

Healing

Also known as

BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

Body Protection Compound-157, Pentadecapeptide BPC 157

FDA approved

Clinical status

Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Phase 2 recruiting (NCT07437547); investigational.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Tissue healing, gut health, injury recovery

Injury recovery, gut healing, joint and tendon repair

How it works

Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.

The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.

Typical dosing

Limited community data available · See research protocols

250-500 mcg twice daily · 1-2x daily

Research dosing

250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection

250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic

Typical duration

4-12 weeks typical

4-12 weeks in most research protocols

Administration

Subcutaneous injection

Subcutaneous injection near injury site, or systemic

Timing

Morning and evening; sometimes aligned with injury-related activity timing

With or without food

Morning and evening (or near injury site timing)

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.)
Nausea (Reported side effect in the source.)
Dizziness (Reported side effect in the source.)

+1 more

Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)

Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.)
Nausea (Listed by the source without frequency or causality information.)
Dizziness (Listed by the source without frequency or causality information.)

+6 more

Injection site reactions (Listed by the source without frequency or causality information.)
Fatigue (Listed by the source without frequency or causality information.)
Headache (Listed by the source without frequency or causality information.)
May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.)
Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.)
Limited long-term human safety data (The source itself notes limited long-term human safety information.)

Research summary

The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.

According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.

References

+3 more

+2 more

Full profile